This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kim, J.-S. Articles by Waldman, T. Search for Related Content PubMed PubMed Citation Articles by Kim, J.-S. Articles by Waldman, T.

B-Raf Is Dispensable for K-Ras-Mediated Oncogenesis in Human Cancer Cells¹

¹ Department of Oncology and ² Tumor Biology Training Program, Lombardi Comprehensive Cancer Center, Georgetown University School of Medicine, Washington, DC

Oncogenic mutations in B-Raf and Kirsten-Ras (K-Ras) are mutually exclusive during human cancer pathogenesis. In an effort to study the biological basis of this epistasis, gene targeting was used to create isogenic sets of human cancer cells differing only in presence or absence of endogenous oncogenic K-Ras or wild-type B-Raf. Whereas cells lacking the K-Ras oncogene were unable to efficiently form xenograft tumors, isogenic cells retaining activated K-Ras but deleted for B-Raf remained highly tumorigenic. Deletion of oncogenic K-Ras failed to reduce the activation state of B-Raf or ERK1/2, despite the requirement of oncogenic K-Ras for tumorigenesis. Genechip analysis revealed numerous genes in which the regulation by oncogenic K-Ras did not require B-Raf. These studies suggest that despite the mutual exclusivity of K-Ras and B-Raf mutations in human cancer and the well-described role for Raf proteins as Ras effectors, B-Raf is dispensable for K-Ras-mediated oncogenesis in a human cancer cell line. Additional studies are required to demonstrate the generalizability of these unexpected findings.

This article has been cited by other articles:

				B. L. Ruis, K. R. Fattah, and E. A. Hendrickson The Catalytic Subunit of DNA-Dependent Protein Kinase Regulates Proliferation, Telomere Length, and Genomic Stability in Human Somatic Cells Mol. Cell. Biol., October 15, 2008; 28(20): 6182 - 6195. [Abstract] [Full Text] [PDF]

				F. J. Fattah, N. F. Lichter, K. R. Fattah, S. Oh, and E. A. Hendrickson Ku70, an essential gene, modulates the frequency of rAAV-mediated gene targeting in human somatic cells PNAS, June 24, 2008; 105(25): 8703 - 8708. [Abstract] [Full Text] [PDF]

				H. Konishi, B. Karakas, A. M. Abukhdeir, J. Lauring, J. P. Gustin, J. P. Garay, Y. Konishi, E. Gallmeier, K. E. Bachman, and B. H. Park Knock-in of Mutant K-ras in Nontumorigenic Human Epithelial Cells as a New Model for Studying K-ras Mediated Transformation Cancer Res., September 15, 2007; 67(18): 8460 - 8467. [Abstract] [Full Text] [PDF]

				J.-S. Kim, C. Lee, C. L. Bonifant, H. Ressom, and T. Waldman Activation of p53-Dependent Growth Suppression in Human Cells by Mutations in PTEN or PIK3CA Mol. Cell. Biol., January 15, 2007; 27(2): 662 - 677. [Abstract] [Full Text] [PDF]

				D. H. Johnson Targeted therapies in combination with chemotherapy in non-small cell lung cancer. Clin. Cancer Res., July 15, 2006; 12(14): 4451s - 4457s. [Abstract] [Full Text] [PDF]

				D. T. Dang, F. Chen, M. Kohli, C. Rago, J. M. Cummins, and L. H. Dang Glutathione S-Transferase {pi}1 Promotes Tumorigenicity in HCT116 Human Colon Cancer Cells Cancer Res., October 15, 2005; 65(20): 9485 - 9494. [Abstract] [Full Text] [PDF]

				S. S. Sridhar, D. Hedley, and L. L. Siu Raf kinase as a target for anticancer therapeutics Mol. Cancer Ther., April 1, 2005; 4(4): 677 - 685. [Abstract] [Full Text] [PDF]